Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

Emmanuel Mignot(Stanford University), Thomas Roth(INTEGRIS Baptist Medical Center), Damien Léger(Université Paris Cité), David Mayleben(Clinical Trial and Consulting), Ingo Fietze(Humboldt-Universität zu Berlin), Gary Zammit(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dalma Seboek Kinter(Idorsia (Switzerland)), Claudio L. Bassetti(Swisscom (Switzerland)), Scott Pain(Idorsia (Switzerland))
The Lancet Neurology
January 19, 2022
Cited by 240


Related Papers